报价延迟最少15分钟:2025/11/16 15:48 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.83 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-13.07/-36.00
|
|
企业价值
37.01M
|
| 资产负债 |
|
每股账面净值
5.02
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 15:48 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
